Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Nanzer, AM; Menzies-Gow, A (2014)
Publisher: Co-Action Publishing
Journal: European Clinical Respiratory Journal
Types: Article
Subjects: Review Article, phenotypes, comorbidities, new biological treatments, severe asthma, Severe asthma, co-morbidities, phenotypes, new biological treatments
Asthma is a chronic inflammatory disease that has reached epidemic proportions worldwide. It is treatable in the majority of patients, but there is no cure. Moreover, a proportion of patients suffer from severe, difficultto- control disease with daily symptoms and high morbidity, making it imperative that we continue to improve our understanding of the underlying mechanisms of this disease. Severe asthma is a heterogeneous condition. A systematic approach to identify specific asthma phenotypes, including clinical characteristics and inflammatory processes, is the first step toward individualized, logical therapy. This review focuses on the need to characterize severe asthma phenotypes and on novel, targeted molecular treatment options currently under development.Keywords: severe asthma; comorbidities; phenotypes; new biological treatments(Published: 5 June 2014)Citation: European Clinical Respiratory Journal 2014, 1: 24356 - http://dx.doi.org/10.3402/ecrj.v1.24356
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Martinez FD, Vercelli D. Asthma. Lancet. 2013; 382: 1360 72.
    • 2. BTS/SIGN. British guideline on the management of asthma. A national clinical guideline. 2008. British Thoracic Society and Scottish Intercollegiate Guidelines Network (SIGN). Available from: http://www.sign.ac.uk/guidelines/fulltext/101/index.html (Revised January 2012).
    • 3. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004; 170: 836 44.
    • 4. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF. Systematic assessment of difficult-to-treat asthma. Eur Respir J. 2003; 22: 478 83.
    • 5. Heaney LG, Conway E, Kelly C, Johnston BT, English C, Stevenson M, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax. 2003; 58: 561 6.
    • 6. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43: 343 73.
    • 7. Moore WC. Update in asthma 2007. Am J Respir Crit Care Med. 2008; 177: 1068 73.
    • 8. Chung SD, Chen PY, Lin HC, Hung SH. Comorbidity profile of chronic rhinosinusitis: a population-based study. The Laryngoscope. 2014. doi: 10.1002/lary.24581.
    • 9. Choi JH, Kim MA, Park HS. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol. 2014; 14: 1 6.
    • 10. Harding SM, Allen JE, Blumin JH, Warner EA, Pellegrini CA, Chan WW. Respiratory manifestations of gastroesophageal reflux disease. Ann N Y Acad Sci. 2013; 1300: 43 52.
    • 11. Kiljander TO, Salomaa ER, Hietanen EK, Terho EO. Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole. Chest. 1999; 116: 1257 64.
    • 12. Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013; 13: 78 86.
    • 13. Sideleva O, Dixon A. The many faces of asthma in obesity. J Cell Biochem. 2014; 115: 421 6. doi: 10.1002/jcb.24678.
    • 14. Gibson PG. Obesity and asthma. Ann Am Thorac Soc. 2013; 10: S138 42.
    • 15. Toh JJ, Pasupathy S, Poopalalingam RA, Koh MS. Can bariatric surgery be performed safely in patients with severe treatment-resistant asthma? Obes Surg. 2014; 24: 334 6.
    • 16. Periyalil HA, Gibson PG, Wood LG. Immunometabolism in obese asthmatics: are we there yet? Nutrients. 2013; 5: 3506 30.
    • 17. Desai D, Newby C, Symon FA, Haldar P, Shah S, Gupta S, et al. Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma. Am J Respir Crit Care Med. 2013; 188: 657 63.
    • 18. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J. 2006; 27: 615 26.
    • 19. Salo PM, Arbes SJ, Jr, Sever M, Jaramillo R, Cohn RD, London SJ, et al. Exposure to Alternaria alternata in US homes is associated with asthma symptoms. J Allergy Clin Immunol. 2006; 118: 892 8.
    • 20. Bush RK, Prochnau JJ. Alternaria-induced asthma. J Allergy Clin Immunol. 2004; 113: 227 34.
    • 21. Smits WL, Letz KL, Evans TS, Giese JK. Evaluating the response of patients undergoing both allergy skin testing and in vitro allergy testing with the ImmunoCAP Technology System. J Am Acad Nurse Pract. 2003; 15: 415 23.
    • 22. Bousquet PJ, Hooper R, Kogevinas M, Jarvis D, Burney P. Number of allergens to be tested to assess allergenic sensitization in epidemiologic studies: results of the European Community Respiratory Health Survey I. Clin Exp Allergy. 2007; 37: 780 7.
    • 23. O'Driscoll BR, Powell G, Chew F, Niven RM, Miles JF, Vyas A, et al. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy. 2009; 39: 1677 83.
    • 24. Hudgel DW, Shucard DW. Coexistence of sleep apnea and asthma resulting in severe sleep hypoxemia. JAMA. 1979; 242: 2789 90.
    • 25. Ekici A, Ekici M, Kurtipek E, Keles H, Kara T, Tunckol M, et al. Association of asthma-related symptoms with snoring and apnea and effect on health-related quality of life. Chest. 2005; 128: 3358 63.
    • 26. Larsson LG, Lindberg A, Franklin KA, Lundback B. Symptoms related to obstructive sleep apnoea are common in subjects with asthma, chronic bronchitis and rhinitis in a general population. Respir Med. 2001; 95: 423 9.
    • 27. Yigla M, Tov N, Solomonov A, Rubin AH, Harlev D. Difficultto-control asthma and obstructive sleep apnea. J Asthma. 2003; 40: 865 71.
    • 28. Julien JY, Martin JG, Ernst P, Olivenstein R, Hamid Q, Lemiere C, et al. Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma. J Allergy Clin Immunol. 2009; 124: 371 6.
    • 29. Alkhalil M, Schulman ES, Getsy J. Obstructive sleep apnea syndrome and asthma: the role of continuous positive airway pressure treatment. Ann Allergy Asthma Immunol. 2008; 101: 350 7.
    • 30. Chan CS, Woolcock AJ, Sullivan CE. Nocturnal asthma: role of snoring and obstructive sleep apnea. Am Rev Respir Dis. 1988; 137: 1502 4.
    • 31. Atlantis E, Sullivan T, Sartorius N, Almeida OP. Changes in the prevalence of psychological distress and use of antidepressants or anti-anxiety medications associated with comorbid chronic diseases in the adult Australian population, 2001 2008. Aust N Z J Psychiatry. 2012; 46: 445 56.
    • 32. Strine TW, Mokdad AH, Balluz LS, Berry JT, Gonzalez O. Impact of depression and anxiety on quality of life, health behaviors, and asthma control among adults in the United States with asthma, 2006. J Asthma. 2008; 45: 123 33.
    • 33. Wang G, Zhou T, Wang L, Fu JJ, Zhang HP, Ji YL. Relationship between current psychological symptoms and future risk of asthma outcomes: a 12-month prospective cohort study. J Asthma. 2011; 48: 1041 50.
    • 34. ten Brinke A, Sterk PJ, Masclee AA, Spinhoven P, Schmidt JT, Zwinderman AH, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J. 2005; 26: 812 8.
    • 35. Martin-Pujol A, Fernandez E, Schiaffino A, Moncada A, Ariza C, Blanch C, et al. Tobacco smoking, exposure to second-hand smoke, and asthma and wheezing in schoolchildren: a crosssectional study. Acta Paediatr. 2013; 102: e305 9.
    • 36. Eisner MD, Yelin EH, Trupin L, Blanc PD. Asthma and smoking status in a population-based study of California adults. Public Health Rep. 2001; 116: 148 57.
    • 37. Pietinalho A, Pelkonen A, Rytila P. Linkage between smoking and asthma. Allergy. 2009; 64: 1722 7.
    • 38. Thomson NC, Chaudhuri R, Heaney LG, Bucknall C, Niven RM, Brightling CE, et al. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. J Allergy Clin Immunol. 2013; 131: 1008 16.
    • 39. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007; 175: 783 90.
    • 40. Comhair SA, Gaston BM, Ricci KS, Hammel J, Dweik RA, Teague WG, et al. Detrimental effects of environmental tobacco smoke in relation to asthma severity. PLoS One. 2011; 6: e18574.
    • 41. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012; 18: 716 25.
    • 42. Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol. 2010; 11: 577 84.
    • 43. Finkelman FD, Katona IM, Urban JF, Jr, Holmes J, Ohara J, Tung AS, et al. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol. 1988; 141: 2335 41.
    • 44. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008; 8: 183 92.
    • 45. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010; 181: 315 23.
    • 46. Hallstrand TS, Moody MW, Aitken ML, Henderson WR, Jr Airway immunopathology of asthma with exercise-induced bronchoconstriction. J Allergy Clin Immunol. 2005; 116: 586 93.
    • 47. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008; 178: 218 24.
    • 48. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009; 180: 388 95.
    • 49. Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med. 2001; 164: S12 7.
    • 50. Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, et al. Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013; 143: 398 405.
    • 51. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005; 115: 459 65.
    • 52. Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013; 187: 804 11.
    • 53. de Llano LP, Vennera Mdel C, Alvarez FJ, Medina JF, Borderias L, Pellicer C, et al. Effects of omalizumab in nonatopic asthma: results from a Spanish multicenter registry. J Asthma. 2013; 50: 296 301.
    • 54. Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taille C, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013; 144: 411 9.
    • 55. Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, et al. Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest. 2010; 120: 2218 29.
    • 56. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007; 176: 1062 71.
    • 57. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al. Effect of SCH55700, a humanized antihuman interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003; 167: 1655 9.
    • 58. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380: 651 9.
    • 59. Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132: 1086 96.e5.
    • 60. Wenzel SE, Balzar S, Ampleford E, Hawkins GA, Busse WW, Calhoun WJ, et al. IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med. 2007; 175: 570 6.
    • 61. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007; 370: 1422 31.
    • 62. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013; 368: 2455 66.
    • 63. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011; 365: 1088 98.
    • 64. Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med. 2013; 13: 11.
    • 65. Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res. 2006; 7: 135.
    • 66. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol. 2001; 108: 430 8.
    • 67. Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui DS, et al. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol. 2001; 125: 177 83.
    • 68. McKinley L, Alcorn JF, Peterson A, Dupont RB, Kapadia S, Logar A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008; 181: 4089 97.
    • 69. Mogil J. Many asthma patients experience persistent symptoms despite appropriate clinical and guideline-based treatment with inhaled corticosteroids. J Am Acad Nurse Pract. 2007; 19: 459 70.
    • 70. Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest. 2008; 134: 394 401.
    • 71. Bhavsar P, Hew M, Khorasani N, Torrego A, Barnes PJ, Adcock I, et al. Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax. 2008; 63: 784 90.
    • 72. Vazquez-Tello A, Semlali A, Chakir J, Martin JG, Leung DY, Eidelman DH, et al. Induction of glucocorticoid receptor-beta expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines. Clin Exp Allergy. 2010; 40: 1312 22.
    • 73. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009; 373: 1905 17.
    • 74. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005; 60: 1012 8.
    • 75. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006; 354: 697 708.
    • 76. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med. 2006; 174: 753 62.
    • 77. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, et al. A randomized, double-blind, placebocontrolled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009; 179: 549 58.
    • 78. Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013; 188: 1294 302.
    • 79. Parker JM, Oh CK, LaForce C, Miller SD, Pearlman DS, Le C, et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med. 2011; 11: 14.
    • 80. Edwards MJ. Therapy directed against thymic stromal lymphopoietin. Drug News Perspect. 2008; 21: 312 6.
    • 81. Catley MC, Coote J, Bari M, Tomlinson KL. Monoclonal antibodies for the treatment of asthma. Pharmacol Ther. 2011; 132: 333 51.
    • 82. Barnes PJ. New therapies for asthma: is there any progress? Trends Pharmacol Sci. 2010; 31: 335 43.
    • 83. Anderson GP. Prospects for an asthma vaccine. Respirology. 2010; 15: 902 8.
    • 84. Black PN, Scragg R. Relationship between serum 25- hydroxyvitamin d and pulmonary function in the third National Health and Nutrition Examination Survey. Chest. 2005; 128: 3792 8.
    • 85. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006; 134: 1129 40.
    • 86. Aloia JF, Li-Ng M. Re: epidemic influenza and vitamin D. Epidemiol Infect. 2007; 135: 1095 6; author reply 1097 8.
    • 87. Bener A, Ehlayel MS, Tulic MK, Hamid Q. Vitamin D deficiency as a strong predictor of asthma in children. Int Arch Allergy Immunol. 2012; 157: 168 75.
    • 88. Paul G, Brehm J, Alcorn JF, Holguin F, Aujla S, Celedon JC. Vitamin D and asthma. Am J Respir Crit Care Med. 2012; 185: 124 32.
    • 89. Brehm JM, Celedon JC, Soto-Quiros ME, Avila L, Hunninghake GM, Forno E, et al. Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med. 2009; 179: 765 71.
    • 90. Gupta A, Sjoukes A, Richards D, Banya W, Hawrylowicz C, Bush A, et al. Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. Am J Respir Crit Care Med. 2011; 184: 1342 9.
    • 91. Nanzer AM, Chambers ES, Ryanna K, Richards DF, Black C, Timms PM, et al. Enhanced production of IL-17A in patients with severe asthma is inhibited by 1alpha,25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion. J Allergy Clin Immunol. 2013; 132: 297 304.e3.
    • 92. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013; 68: 322 9.
    • 93. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev. 2000: CD000391.
    • 94. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010; 181: 116 24.
    • 95. Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL, et al. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013; 132: 1295 302.
  • No related research data.
  • No similar publications.